Dr Margaret Cecilia Green, DO in Portsmouth, VA - Medicare Pathology

Dr Margaret Cecilia Green, DO is a medicare enrolled "Dermatology - Dermatopathology" physician in Portsmouth, Virginia. She went to West Virginia School Of Osteopathic Medicine and graduated in 2013 and has 11 years of diverse experience with area of expertise as Pathology. She is a member of the group practice Hct Pathology Services Llc and her current practice location is 620 John Paul Jones Cir Bldg 3, Portsmouth, Virginia. You can reach out to her office (for appointments etc.) via phone at (757) 953-0307.

Dr Margaret Cecilia Green is licensed to practice in Virginia (license number 0102207964) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1477992881.

Contact Information

	Dr Margaret Cecilia Green, DO
	620 John Paul Jones Cir Bldg 3, Portsmouth, VA 23708-2111
	(757) 953-0307
	Not Available

Physician's Profile

Full Name	Dr Margaret Cecilia Green
Gender	Female
Speciality	Pathology
Experience	11 Years
Location	620 John Paul Jones Cir Bldg 3, Portsmouth, Virginia
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Margaret Cecilia Green attended and graduated from West Virginia School Of Osteopathic Medicine in 2013

NPI Data:

NPI Number: 1477992881
Provider Enumeration Date: 06/19/2013
Last Update Date: 08/18/2023

Medicare PECOS Information:

PECOS PAC ID: 9739405226
Enrollment ID: I20210521001897

Medical Identifiers

Medical identifiers for Dr Margaret Cecilia Green such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1477992881	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ND0900X	Dermatology - Dermatopathology	H0090997 (Maryland)	Secondary
207ND0900X	Dermatology - Dermatopathology	0102207964 (Virginia)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Hct Pathology Services Llc	2961509856	18

News Archive

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

U.S. veterans diagnosed with gastroesophageal reflux disease (GERD) are frequently prescribed doses of proton pump inhibitors (PPIs), such as omeprazole (commonly known by brand names such as Prilosec), that are much higher than recommended -- and they are kept on the drug far too long, according to a new Northwestern Medicine- study.

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company's lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

Findings conflict with traditional view of how epileptic seizures begin

The first study to examine the activity of hundreds of individual human brain cells during seizures has found that seizures begin with extremely diverse neuronal activity, contrary to the classic view that they are characterized by massively synchronized activity.

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited's network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Margaret Cecilia Green allows following entities to bill medicare on her behalf.

Entity Name	Hct Pathology Services Llc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1598831976 PECOS PAC ID: 2961509856 Enrollment ID: O20070530000295

News Archive

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Findings conflict with traditional view of how epileptic seizures begin

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Margaret Cecilia Green is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Margaret Cecilia Green, DO 10718 Pheasant Dr, Clarksburg, MD 20871-8523 Ph: (843) 343-6293	Dr Margaret Cecilia Green, DO 620 John Paul Jones Cir Bldg 3, Portsmouth, VA 23708-2111 Ph: (757) 953-0307

News Archive

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Findings conflict with traditional view of how epileptic seizures begin

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Dermatology Doctors in Portsmouth, VA

Dr. Anis Miladi, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-0311
Dr. Megan Ann Brelsford, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 620 John Paul Jones Cir, Charette Health Care Center, Portsmouth, VA 23708 Phone: 757-953-0291 Fax: 757-953-0862
Dr. Trisha Clarke Beute, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 620 John Paul Jones Cir, Nmcp- Dept Of Dermatology, Portsmouth, VA 23708 Phone: 757-953-0311
John Peters, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-0291
Dr. Aaron Cantor, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir Ste 275, Portsmouth, VA 23708 Phone: 757-953-5000
Dr. Rachel Michal Ellis, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-9808

Dr Margaret Cecilia Green, DO - Medicare Pathology in Portsmouth, VA

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Findings conflict with traditional view of how epileptic seizures begin

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Medicare Reassignments

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Findings conflict with traditional view of how epileptic seizures begin

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Findings conflict with traditional view of how epileptic seizures begin

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Dermatology Doctors in Portsmouth, VA